论文部分内容阅读
为了给临床提供特异有效的治疗婴幼儿轮状病毒感染的生物制剂，以ＳＡ１１轮状病毒免疫受孕乳牛，制备抗轮状病毒免疫牛初乳，从临床治疗角度，对８０例婴幼儿急性轮状病毒感染性腹泻，４３例应用抗轮状病毒牛初乳治疗，３７例应用思密达治疗，对两组进行了疗效对比观察。结果表明：抗轮状病毒免疫牛初乳治疗组的总有效率，显效率和７２小时粪便病毒转阴率分别达９１％，７９％和８９％；而思密达治疗组的疗效及７２小时大便病毒转阴率则相应为４１％，２４％和３９％，差异均有非常显著意义。为临床治疗婴幼儿轮状病毒感染性腹泻提供了安全有效，特异性强的治疗手段
In order to provide specific and effective biological agents for the treatment of rotavirus infection in infants and young children, SA11 rotavirus was used to immunize the pregnant cows to prepare anti-rotavirus immune colostrum. From the perspective of clinical treatment, 80 cases of acute rotavirus Virus-infected diarrhea, 43 cases of anti-rotavirus colostrum treatment, 37 cases treated with Smectite, the two groups were compared the efficacy of treatment. The results showed that the total effective rate, the effective rate and the negative rate of stool virus in 72 hours were 91%, 79% and 89% respectively in the treatment group with anti-rotavirus immunization colostrum, while the efficacy and 72 hours in the smecta treatment group The stool virus negative conversion rates were 41%, 24% and 39%, respectively, with significant differences. For the clinical treatment of infantile rotavirus infectious diarrhea provides a safe and effective, specific and strong treatment